Grovet gaat verhuizen! In verband met deze verhuizing zijn wij gesloten van 29 t/m 31 mei. Gedurende deze periode worden er geen bestellingen verwerkt en verzonden. Het is wel mogelijk om uw bestelling te plaatsen. Meer informatie over de verhuizing kunt u hier vinden. Heeft u verder nog vragen of opmerkingen, aarzel dan niet om contact met ons op te nemen via info@grovet.com

 

Proteq West Nile 2x1 dose

SKU
126435
Merk:
Boehringer Ingelheim
Batch:
F22266
Houdbaar tot:
25-Apr-2025
Registratienummer:
NL: REG NL 107618

Staat het registratienummer van uw land er niet tussen? Dan betreft het een cascade product. Klik hier voor meer info.

Active immunisation against West Nile virus.

Disclaimer: Product op de foto kan afwijken van het daadwerkelijke product.

Proteq West Nile 2x1 dose + syringe

Suspension for injection containing West Nile recombinant canarypox virus (vCP2017). 

The vaccine strain vCP2017 is a recombinant canarypox virus expressing the preM/E genes of West Nile virus. After inoculation, the virus does not multiply in the horse but expresses the protective proteins. As a consequence, these proteins induce protective immunity against equine West Nile disease.

Indication
Active immunisation of horses from 5 months of age against West Nile disease. Proteq West Nile reduces the number of viraemic horses. If clinical signs are present, their duration and severity are reduced. 
Onset of immunity: 4 weeks after the first dose of the primary vaccination course. In order to achieve full protection, the full vaccination course of two doses must be given.  

Duration of immunity: 1 year after a full primary vaccination course of two injections.

Route of administation and dosage
For intramuscular use.
Shake gently before use. 

Administer one dose of 1ml, by intramuscular injection, preferably in the neck region, according to the following schedule:
- Primary vaccination course: first injection from 5 months of age, second injection 4-6 weeks later
- Revaccination: a sufficient degree of protection should be achieved after an annual booster injection with a single dose although this schedule has not been fully validated.

© 2024 Grovet B.V. All rights reserved.